Martin Sands has identified and pursued numerous compelling opportunities in his career and in regard to bio science , he continues to identify and pursue transformative / breakthrough opportunities to enhance our health and quality of life.
Martin lead the $35million series C round for Safeheal Therapeutics which is truly a revolutionary approach to colorectal surgical procedures. The current Standard of Care {SOC} generally results in a diverting ostomy which is known as a colostomy bag, a highly physical and emotional disruptive situation. Safeheal’s technology is a significant improvement and often results in the avoidance of the diverting ostomy.
Optmed was a deal introduced to him 15 years ago that would be a healthy alternative to Closure medicals Dermabond. He was named Co – chairman and helped the company navigate to a successful FDA Approval and the development of a commercially viable, revenue generating laboratory in Spain.
Martin Sands has long recognized the profound potential of the life sciences sector to improve health outcomes and extend quality of life. His focus spans innovative therapeutics, diagnostics, and medical technologies that address unmet clinical needs and advance human wellness. Reflecting on his work with Osteal Therapeutics, Inc., he notes that hip and knee replacements—already among the most common surgeries—are projected to triple by 2040, while current treatments for periprosthetic joint infections are associated with high morbidity and reduced quality of life. Osteal’s novel therapeutic approach exemplifies the type of innovation that can transform patient outcomes.
Throughout his career, Martin has partnered with visionary founders, scientists, and investors driving progress in biotechnology and healthcare. He continues to seek out transformative life science opportunities that merge scientific innovation with sound business execution to create lasting impact.
Martin Sands has long recognized Artificial Intelligence as one of the most transformative forces shaping modern technology and business. He views AI as an accelerator of innovation across nearly every sector, enhancing efficiency, precision, and decision-making capabilities.
In recent years, Martin has pursued and invested in several AI-driven ventures, focusing on companies applying machine learning and data intelligence to solve complex real-world problems. Martin was Co-Managing Member of SPV in AlphaSense, an AI-based market intelligence platform with investment from Alphabet’s CapitalG. AlphaSense CEO Jack Kokko was recognized as EY Entrepreneur of the Year in 2023. His interest continues to center on AI platforms that enable smarter systems, improved diagnostics, and automation that fundamentally reshapes how industries operate.
Throughout his career, Martin Sands has viewed software as the foundation of innovation, powering transformation across industries. He has consistently pursued opportunities where software solutions drive efficiency, scalability, and measurable impact.
Martin has been involved with a range of software ventures, from early-stage startups to mature enterprises leveraging cloud computing, automation, and advanced analytics. His continued interest lies in platforms that redefine traditional business models, streamline operations, and enable new ways of delivering value in a connected world. From this interest, he invested into the global logistics innovator Flexport and AI Agentics company Thoughtspot.
With the increasing complexity of digital infrastructure, Martin Sands recognizes cybersecurity as one of the most critical areas shaping the future of technology and global commerce. He views it as both a challenge and an opportunity—demanding constant innovation to stay ahead of evolving threats.
Over the years, Martin has invested in and advised companies focused on data protection, secure communications, and threat intelligence. He remains deeply engaged in exploring advancements that safeguard privacy, integrity, and trust across industries where digital resilience has become essential. As a result of his strong interest in this area, he has invested into the leader in DSPM (Data security posture management) and perhaps one of the leaders in deep intelligent data security across the entire enterprise, Bigid. He also invested into Level Blue, best known as one of the world’s largest pure‑play Managed Security Service Providers (MSSPs), delivering 24/7 Managed Detection & Response (MDR), cloud security, and threat intelligence at global scale.
Martin Sands sees quantum computing as one of the most promising frontiers in science and technology—an innovation poised to redefine computation, problem-solving, and discovery itself. He is particularly drawn to its potential to accelerate breakthroughs in medicine, materials science, and cryptography.
Through his focus on revolutionary and disruptive technologies, Martin continues to evaluate quantum-driven ventures that push the limits of what’s computationally possible. His interest centers on supporting visionary teams that are turning theoretical potential into real-world transformation. His investment into Classiq reflects his confidence in the enormous future for quantum computing and at the software level sits Classiq Technologies making it easier to design, optimize, and run complex quantum circuits. In other words, Classiq provides software that enables the design, optimization, analysis, and execution of quantum algorithms.